The Mainz-based biopharmaceutical company said the closures will affect about 1,800 employees at sites in Tübingen, Marburg and Idar-Oberstein.
BioNTech’s decision follows a comprehensive strategic review aimed at aligning the company’s manufacturing capacity with its clinical pipeline and long-term business direction